Although it was biologically plausible that CP IgA-positive COVID-19 patients had a poorer prognosis, no statistical difference in 30-day mortality was observed in either CP IgA-positive or CP IgG-positive COVID-19 patients. This evidence concerns the gene CD79A and COVID-19.